Table 1.
List of enriched up/down-regulated pathways.
| Group | Pathway | Fold enrichment | P value | Genes |
|---|---|---|---|---|
| Group A | Tyrosine metabolism | 20.7 | 8.3E−04 | PNMT, MAOA, ADH1B, AOX1 |
| Cytokine-cytokine receptor interaction | 3.7 | 4.0E−02 | LEP, CCL3L3, IL1R2, IL18, IFNLR1 | |
| Amphetamine addiction | 8.2 | 4.9E−02 | GRIA1, MAOA, PPP1R1B | |
| Drug metabolism—cytochrome P450 | 8.0 | 5.1E−02 | MAOA, ADH1B, AOX1 | |
| Neuroactive ligand-receptor interaction | − 5.3 | 4.0E−03 | GRIN2A, GABRA4, TACR1, GRPR, MCHR1, NTSR1 | |
| Cytokine-cytokine receptor interaction | − 5.1 | 1.4E−02 | IL1A, CSF2, IL1B, TNFRSF9, CXCR4 | |
| Calcium signaling pathway | − 5.5 | 3.2E−02 | GRIN2A, TACR1, GRPR, NTSR1 | |
| Salmonella infection | − 8.9 | 4.2E−02 | IL1A, CSF2, IL1B | |
| Hematopoietic cell lineage | − 8.5 | 4.5E−02 | IL1A, CSF2, IL1B | |
| Rheumatoid arthritis | − 8.4 | 4.6E−02 | IL1A, CSF2, IL1B | |
| Group B | Drug metabolism—cytochrome P450 | 15.2 | 3.6E−05 | ADH4, MAOA, ADH1B, ADH1A, AOX1, FMO2 |
| Tyrosine metabolism | 24.6 | 4.1E−05 | ADH4, MAOA, ADH1B, ADH1A, AOX1 | |
| Retinol metabolism | 10.7 | 5.5E−03 | ADH4, ADH1B, ADH1A, AOX1 | |
| Fatty acid degradation | 12.3 | 2.3E−02 | ADH4, ADH1B, ADH1A | |
| Glycolysis/gluconeogenesis | 7.7 | 5.5E−02 | ADH4, ADH1B, ADH1A | |
| Chemical carcinogenesis | 6.4 | 7.5E−02 | ADH4, ADH1B, ADH1A | |
| Cell adhesion molecules (CAMs) | − 4.6 | 8.6E−06 | ICAM2, SELE, SELP, HLA-DMB, CDH3, CLDN3, CDH1, PECAM1, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DQA1, HLA-DRB1, HLA-DQB1 | |
| Allograft rejection | − 8.9 | 1.1E−04 | HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| Basal cell carcinoma | − 6.9 | 1.3E−04 | WNT10B, SHH, WNT10A, WNT7B, PTCH2, FZD10, WNT2, WNT4 | |
| Type I diabetes mellitus | − 7.8 | 2.3E−04 | HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| Inflammatory bowel disease (IBD) | − 5.8 | 3.8E−04 | HLA-DMB, RORC, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| Autoimmune thyroid disease | − 6.3 | 7.5E−04 | HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| Pancreatic secretion | − 4.0 | 3.5E−03 | CPA3, CPB1, FXYD2, KCNQ1, PLA2G2A, CLCA2, CD38, ATP1A2 | |
| cAMP signaling pathway | − 2.6 | 9.2E−03 | GRIA2, CHRM1, NPY, FXYD2, PDE3B, CNGA1, ADRB1, ATP1A2, SSTR1, SSTR2, GRIN1 | |
| Hippo signaling pathway | − 2.8 | 1.5E−02 | WNT10B, WNT10A, CDH1, WNT7B, RASSF6, FZD10, WNT2, BMP7, WNT4 | |
| Wnt signaling pathway | − 2.7 | 2.7E−02 | WNT10B, WNT10A, SFRP2, MMP7, WNT7B, FZD10, WNT2, WNT4 | |
| Signaling pathways regulating pluripotency of stem cells | − 2.7 | 2.9E−02 | WNT10B, WNT10A, WNT7B, IGF1, FZD10, WNT2, ISL1, WNT4 | |
| Pathways in cancer | − 1.8 | 3.9E−02 | WNT10B, WNT10A, WNT7B, PTCH2, CBLC, KLK3, FZD10, IGF1, MMP9, SHH, GNG4, CDH1, WNT2, NKX3-1, WNT4 | |
| cGMP-PKG signaling pathway | − 2.4 | 5.1E−02 | NOS3, FXYD2, PDE2A, PDE3B, CNGA1, ADRB1, ATP1A2, ADRA2A | |
| Adrenergic signaling in cardiomyocytes | − 2.4 | 7.3E−02 | MYL4, TNNT2, FXYD2, KCNQ1, ADRB1, ATP1A2, CACNG4 | |
| Cardiac muscle contraction | − 3.1 | 7.5E−02 | MYL4, TNNT2, FXYD2, ATP1A2, CACNG4 | |
| Group C | Tyrosine metabolism | 45.4 | 2E−3 | MAOA, ADH1B, AOX1 |
| Drug metabolism—cytochrome P450 | 23.3 | 6E−3 | MAOA, ADH1B, AOX1 | |
| Tryptophan metabolism | 26.5 | 6.8E−2 | MAOA, AOX1 | |
| Group D | Cytokine-cytokine receptor interaction | 4.5 | 5.1E−2 | CCL3L3, IL1R2, IL18, IFNLR1 |
| Neuroactive ligand-receptor interaction | − 5.4 | 1.1E−2 | GRIN2A, GABRA4, TACR1, GRPR, NTSR1 | |
| Calcium signaling pathway | − 6.7 | 1.9E−2 | GRIN2A, TACR1, GRPR, NTSR1 | |
| Salmonella infection | − 10.8 | 2.8E−2 | IL1A, CSF2, IL1B | |
| Hematopoietic cell lineage | − 10.3 | 3.1E−2 | IL1A, CSF2, IL1B | |
| Rheumatoid arthritis | − 10.2 | 3.2E−2 | IL1A, CSF2, IL1B | |
| Amoebiasis | − 8.5 | 4.4E−2 | CSF2, SERPINB2, IL1B | |
| Measles | − 6.7 | 6.7E−2 | IL1A, IL1B, TACR1 | |
| Circadian rhythm | − 19.3 | 9.5E−2 | PER3, NR1D1 | |
| Group E | Drug metabolism—cytochrome P450 | 10.5 | 3.1E−2 | ADH4, ADH1A, FMO2 |
| Rap1 signaling pathway | 4.5 | 5.2E−2 | FPR1, KDR, FGFR4, RAPGEF5 | |
| Cell adhesion molecules (CAMs) | − 4.8 | 0.000 | ICAM2, SELE, SELP, HLA-DMB, CDH3, CLDN3, CDH1, PECAM1, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DQA1, HLA-DRB1, HLA-DQB1 | |
| Type I diabetes mellitus | − 8.2 | 0.000 | HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| Antigen processing and presentation | − 5.2 | 1E−3 | CD74, HLA-DMB, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| cAMP signaling pathway | − 2.7 | 7E-3 | GRIA2, CHRM1, NPY, FXYD2, PDE3B, CNGA1, ADRB1, ATP1A2, SSTR1, SSTR2, GRIN1 | |
| Proteoglycans in cancer | − 2.7 | 7E−3 | WNT10B, WNT10A, HPSE2, WNT7B, CBLC, IGF1, FZD10, WNT2, HOXD10, MMP9, WNT4 | |
| Wnt signaling pathway | − 2.8 | 2.1E−2 | WNT10B, WNT10A, SFRP2, MMP7, WNT7B, FZD10, WNT2, WNT4 | |
| Signaling pathways regulating pluripotency of stem cells | − 2.8 | 2.3E−2 | WNT10B, WNT10A, WNT7B, IGF1, FZD10, WNT2, ISL1, WNT4 | |
| Pathways in cancer | − 1.9 | 2.7E−2 | WNT10B, WNT10A, WNT7B, PTCH2, CBLC, KLK3, FZD10, IGF1, MMP9, SHH, GNG4, CDH1, WNT2, NKX3-1, WNT4 | |
| Phagosome | − 2.6 | 3.2E−2 | HLA-DMB, SFTPA2, HLA-DRA, HLA-DOA, HLA-DQA2, HLA-DRB1, HLA-DQA1, HLA-DQB1 | |
| Hippo signaling pathway | − 2.6 | 3.3E−2 | WNT10B, WNT10A, CDH1, WNT7B, FZD10, WNT2, BMP7, WNT4 | |
| cGMP-PKG signaling pathway | − 2.5 | 4.1E−2 | NOS3, FXYD2, PDE2A, PDE3B, CNGA1, ADRB1, ATP1A2, ADRA2A | |
| Adrenergic signaling in cardiomyocytes | − 2.5 | 6E−2 | MYL4, TNNT2, FXYD2, KCNQ1, ADRB1, ATP1A2, CACNG4 | |
| Cardiac muscle contraction | − 3.3 | 6.5E−2 | MYL4, TNNT2, FXYD2, ATP1A2, CACNG4 | |
| Dilated cardiomyopathy | − 2.9 | 9E−2 | DES, TNNT2, ADRB1, IGF1, CACNG4 |
Group A: DEGs between DEX and ETH treated for short duration (16 h); Group B: DEGs between DEX and ETH treated for longer duration (7 d); Group C: DEGs that overlapping between Group A and Group B; Group D: Uniquely expressed DEGs of HTM cells exposed for 16 h (Group A minus Group C); Group E: Uniquely expressed DEGs of HTM cells exposed for 7 d (Group B minus Group C).